Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 454
- Registration Number
- NCT03737981
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03735875
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03713580
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT03710772
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 64
- Registration Number
- NCT03709758
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 30
- Registration Number
- NCT03708003
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭IOSI - Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭Universitätsspital Basel, Basel, Switzerland
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03701321
- Locations
- 🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 720
- Registration Number
- NCT03701282
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
Venetoclax Registry
- Conditions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 100
- Registration Number
- NCT03662724
- Locations
- 🇩🇪
Medical School Hannover, Hannover, Niedersachsen, Germany
Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT03661307
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.